Clinical Trials Browser

Phase 2 × Hepatectomy × 90 days × Clear all

NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms